Anzeige
Mehr »
Login
Freitag, 23.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Ist das Joe Bidens Lieblingsaktie und zugleich das Übernahmeziel Nr. 1?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856273 ISIN: JP3942400007 Ticker-Symbol: YPH 
Tradegate
23.04.21
09:54 Uhr
12,980 Euro
+0,205
+1,60 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
ASTELLAS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASTELLAS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,72512,96013:54
12,71512,96513:54

Aktuelle News zur ASTELLAS PHARMA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoResverlogix Corp: Resverlogix spinout company signs deal with Astellas3
DiAstellas innovation awards offer up ideas to ease cancer patients' pandemic burdens3
MoSeagen, Astellas eye fast FDA review for Padcev's expanded bladder cancer use, with all-important Keytruda combo data to come3
ASTELLAS PHARMA Aktie jetzt für 0€ handeln
MoFDA accepts Seagen, Astellas' enfortumab vedotin applications in urothelial cancer2
14.04.On a roll, Gilead snags 2nd Trodelvy nod-in bladder cancer-but Seagen and Astellas have set the bar high28
31.03.Astellas gene therapy repairs damage in neurodegenerative disease models5
30.03.Astellas' Xospata meets overall survival endpoint in late-stage blood cancer study5
30.03.Astellas' Gilteritinib Meets Overall Survival Endpoint In Phase 3 Trial On Acute Myeloid Leukemia329TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that a phase 3 confirmatory trial of XOSPATA or gilteritinib in patients with relapsed (disease that has returned) or refractory...
► Artikel lesen
26.03.Astellas wins FDA approval for new Myrbetriq indication and formulation2
26.03.Astellas: FDA Approves Myrbetriq For Children With Neurogenic Detrusor Overactivity552TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said Friday that the U.S. Food and Drug Administration approved Myrbetriq (mirabegron extended-release tablets) for the treatment of...
► Artikel lesen
26.03.Astellas Gets Positive CHMP Opinion For XTANDI On Metastatic Hormone-Sensitive Prostate Cancer602TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion...
► Artikel lesen
26.03.Astellas and Pfizer's XTANDI gets EMA positive opinion for additional indication6
26.03.The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs11
26.03.EMA accepts Astellas/Seagen's enfortumab vedotin for review5
26.03.EMA accepts Astellas, Seagen's enfortumab vedotin application in urothelial cancer3
23.03.Astellas Pharma Inc. -- Moody's downgrades Astellas' rating to A3; outlook stable3
25.02.ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer6
19.02.Astellas' non hormonal therapy shows positive effect on hot flashes in late-stage trial5
19.02.Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies4
19.02.Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff77
Seite:  Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1